Table 3.
Summary of the phase 2 and phase 3 results.
| Therapeutic drug | Phase | Primary end point results (Mean change from baseline) | Secondary end point results (Mean change from baseline) | Adverse effects |
|---|---|---|---|---|
| Efgartigimod | 2 | Safe and well tolerated | QMG −5.7 MG-ADL −4.4 MG-QoL15r −6 |
No serious side effects Most common side effects: headaches, rhinitis, pruritis |
| Efgartigimod | 3 | MG-ADL responders (68%) | QMG responders (63%) Early MG-ADL responders (57%) |
5% patients had serious side effects. Most common side effects: headaches, nasopharyngitis |
| Rozanolixizomab | 2 | QMG −1.8 | MG-ADL −1.8 MGC −3.1 |
No serious side effects Most common side effects: headaches |
| Rozanolixizomab | 3 | 7 mg/kg MG-ADL −3.70 10 mg/kg MG-ADL −3.40 |
7 mg/kg MGC -5.93, QMG −5.40 10 mg/kg QMG −6.67, QMG −7.55 |
No serious side effects Most common side effects: headaches diarrhea, nausea, pyrexia |
| Nipocalimab | 2 | 30 mg/kg q4wkly MG-ADL −3.7 60mh/kgQ2wkly |
No serious side effects Most common side effects: diarrhea, headache, nasopharyngitis |
|
| Batoclimab | 2 | Safe and well tolerated 680 mg SC Total IgG −776.1. 340 mg SC Total IgG −59.3 |
MG-ADL −3.8 QMG −3.9 MGC −8.0 |
No serious side effects |